ChemoFx® Valuable Tool in Treating Cancer
February 16, 2006
A new study published in the International Journal of Gynecological Cancer (IJGC) shows that women with ovarian cancer lived three times longer without experiencing a worsening of the disease when treated with drugs determined to be effective in treating their individual tumor. The new study reports the results of a broad-based trial involving the selection and administration of chemotherapy drugs based upon the results of chemoresponse assay testing with the ChemoFx assay from Precision Therapeutics. ChemoFx is a cell-based test that quantifies an individual patient's likely tumor response to single or multiple chemotherapeutic agents. Read more at http://pittsburgh.dbusinessnews.com/shownews.php?newsid=61294&type_news=latest.
« Haley Systems to Integrate Business Rules Technology into MRG Software | | Carnegie Learning Helps Change the Way Teachers Teach »
